Overall, our results suggest opposing roles for Cdh1 and AROS in SIRT1 degradation during the development of pulmonary fibrosis and support pinosylvin as a therapeutic agent for human pulmonary fibrosis. Here, SIRT1 is linked to pulmonary fibrosis.